Immunic, Inc. — Q1 2021 Form 10-Q
Business and period: Clinical-stage biopharmaceutical company developing three oral immunology candidates: IMU-838, IMU-935 and IMU-856. This summary covers the three months ended March 31, 2021, compared with Q1 2020 unless otherwise noted. The company had no approved products and no product-sales revenue.
Financial position and results
- Revenue: No product-sales revenue; the filing reports no revenue from product sales to date.
- Expenses and loss: Research and development expense was $11.5 million, up 79% from $6.4 million. General and administrative expense was $20.9 million, up from $2.6 million. Total operating expenses were $32.4 million, versus $9.0 million; net loss was $34.5 million, versus $8.5 million. Basic and diluted net loss per share was $1.63, versus $0.79.
- Margins: Not meaningful for a company without product-sales revenue.
- Cash flow and liquidity: Operating cash use was $12.9 million, compared with $11.0 million. Cash and cash equivalents were $114.8 million at quarter-end, down from $127.5 million at December 31, 2020. Management expected existing funds to support operations beyond 12 months from the financial-statement issuance date.
- Balance sheet and debt: Total assets were $154.7 million and total liabilities $17.3 million. Current assets were $120.3 million versus current liabilities of $16.4 million. No EIB loan funds had been drawn; the company had access to a loan facility of up to €24.5 million, subject to milestones and other terms. Operating lease liabilities totaled $1.345 million on a present-value basis.
- Accumulated deficit: $138.5 million at March 31, 2021, compared with $103.9 million at year-end 2020.
Material changes and notable items
- G&A expense rose by $18.3 million, primarily due to a $17.25 million settlement of 4SC AG royalty obligations. The settlement was funded half in cash and half in company shares; the stock portion was recorded at $8.625 million. The agreement eliminated future payment obligations to 4SC under that royalty.
- R&D expense increased by $5.1 million, reflecting COVID-19 trial costs, IMU-838 drug supply, preparation for a possible Phase 3 multiple-sclerosis program, and increased ulcerative-colitis trial costs.
- Other expense was $2.1 million, versus other income of $0.5 million in Q1 2020, primarily reflecting a $2.5 million foreign-exchange loss on an intercompany loan and lower Daiichi Sankyo-related reimbursements.
- Cash used in operations exceeded the prior-year quarter, while no cash financing proceeds were raised in Q1 2021. The company issued 581,199 shares in connection with the 4SC settlement.
Outlook, programs and risks
- Management expected operating expenses and losses to increase as clinical development advances and noted that quarterly spending may fluctuate. The company may need additional capital; future financing could dilute shareholders or impose restrictive terms. No specific financial guidance was provided.
- For IMU-838, management reported that Cohort 2 of the EMPhASIS RRMS Phase 2 trial was ongoing and expected to initiate a Phase 3 program in the second half of 2021, subject to regulatory engagement. CALDOSE-1 ulcerative-colitis enrollment was expected to finish in the second half of 2021, with induction-phase top-line data expected in the first half of 2022.
- The PSC proof-of-concept study enrolled 18 patients versus a 30-patient target and had 11 evaluable patients in the per-protocol population. The company reported a statistically significant ALP decrease in that small population; the study was terminated before reaching its intended enrollment, in the context of the pandemic.
- Although management reported clinical activity in the Phase 2 COVID-19 trial, it said a Phase 3 monotherapy program was no longer considered viable within a reasonable timeframe as vaccination advanced. Further antiviral research was planned.
- IMU-935’s Phase 1 multiple-ascending-dose stage had begun; initial patient testing was expected in Q3 2021. IMU-856’s Phase 1 single-ascending-dose stage was complete, with the multiple-ascending-dose stage subject to ethics-committee clearance.
- Principal risks include clinical-trial failure, inability to obtain regulatory approval, need for additional financing, foreign-exchange exposure, and reliance on key personnel. The company reported no material litigation, no material change to its previously disclosed risk factors, and effective disclosure controls.
Investor facts to verify
- Whether clinical milestones and timing—including the RRMS Phase 3 start and UC readout—were achieved, and what subsequent data show.
- How the small, prematurely terminated PSC study affects confidence in the reported result and plans for further testing.
- Cash runway relative to actual trial spending, and the terms, milestone availability and potential revenue-linked payments under the EIB facility.
- The accounting and cash impact of the 4SC settlement, including resale registration and potential share dilution.
- Foreign-exchange sensitivity: management estimated that a hypothetical 10% adverse currency move could reduce German subsidiaries’ net current assets by about $4.6 million and affect quarterly net loss by about $2.8 million.